Earlier this year, HST Global announced that it contracted EBITDA Capital LLC of Newport Beach California and its group of associates to join HST-Global’s efforts in working toward an overall corporate strategy. The company also announced Former United States Congressman Bill Sarpalius, the President and CEO of Advantage Associates International, has been given the role of interfacing with the political community in Washington DC.

Mr. Sarpalius said, “We are excited to be in a position to raise the awareness of both the public and members of the government about HST’s treatment solution. The opportunity of bringing a treatment for late stage cancer is something which we all want to see expanded and made use of in the treatment community.”

Mr. Ron Howell, CEO and President of HST Global commented, “Through the use of the EBITDA Capital resources we at HST Global can focus on the issue of bringing awareness of our treatment and solution for late stage cancer treatment. We want to insure that our treatment is being given every opportunity to be recognized as the medical solution alternative of choice.”

“HST has worked to develop a complete strategy for the success of its program and treatment and is now moving toward a more public awareness platform. We believe that EBITDA and its associates, such as Advantage Associates, will help us get this done,” he continued.

Let us hear your thoughts: HST Global, Inc. Message Board

Last 5 posts by QualityStocks

• November 23rd CEOcast Weekly Newsletter - November 23rd, 2009
• Longwei Petroleum Investment Holdings Ltd. (LPHI) Reports Strong Third Quarter - November 23rd, 2009
• An Opportunity to Get there First in the Media Space - November 23rd, 2009
• Akeena Solar, Inc. (AKNS) Partners with Highland Solar Achieving Canadian Market Penetration - November 23rd, 2009
• Cardio Vascular Medical Device Corp. (CVSL.OB) Applying for Patents in Europe, Canada, and Far East - November 23rd, 2009